Advertisement

Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors

Published:September 26, 2021DOI:https://doi.org/10.1016/j.clcc.2021.09.009

      Abstract

      Background

      The orally administered combination trifluridine/tipiracil has been approved as third line treatment in mCRC, demonstrating survival benefit and acceptable toxicity profile in the phase III RECOURSE study.

      Patient and methods

      We performed a multicenter retrospective real-world analysis of patients with mCRC receiving trifluridine/tipiracil between 2016 and 2019 in eight cancer centers across the United Kingdom.

      Results

      A total of 236 patients were included with median age of 69 years. All patients had received at least 2 lines of fluoropyrimidine-based chemotherapy doublet with oxaliplatin or irinotecan. About 10% of patients had ECOG ≥ 2. Median duration of trifluridine/tipiracil treatment was 3 months with an ORR of 2.1% and disease control rate of 21.6%. Median OS was 7.6 and median PFS 3.3 months. A dose reduction was required in 27% of patients, while 7.6% discontinued treatment due to toxicity. The most common grade 3 toxicities were neutropenia (34%), fatigue (10%), anemia (9%) and febrile neutropenia (5%). Baseline NLR <5 and CEA <200 had favorable prognostic (HR: 0.52 and 0.39, P≤ .001) and predictive value (OR: 4.1 and 6.7, P< .05). Development of grade 3 neutropenia predicted treatment response (OR: 0.32, P< .001). Following treatment with trifluridine/tipiracil 41% were referred for phase I trial or rechallenged with chemotherapy.

      Conclusion

      Trifluridine/tipiracil is well tolerated in refractory mCRC patients with comparable efficacy and toxicity profile to that of the phase III RECOURSE. Pretreatment NLR and CEA could serve as potential markers for patient selection, while treatment-induced grade 3 neutropenia predicted response. Prospective validation is needed.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Colorectal Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. xxx https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer. Accessed 03 Jan 2021.

        • Van Cutsem E
        • Cervantes A
        • Nordlinger B
        • Arnold D.
        Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2014; 25 (Suppl 3:iii1-9): 1-9
        • Emura T
        • Murakami Y
        • Nakagawa F
        • Fukushima M
        • Kitazato K.
        A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
        Int J Mol Med. 2004; 13: 545-549
        • Lenz HJ
        • Stintzing S
        • Loupakis F.
        TAS-102, a novel antitumor agent: a review of the mechanism of action.
        Cancer Treat Rev. 2015; 41: 777-783
        • Marcus L
        • Lemery SJ
        • Khasar S
        • et al.
        FDA Approval Summary: TAS-102.
        Clin Cancer Res. 2017; 23: 2924
        • Mayer RJ
        • Van Cutsem E
        • Falcone A
        • et al.
        Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
        N Engl J Med. 2015; 372: 1909-1919
        • Bachet J-B
        • Wyrwicz L
        • Price T
        • et al.
        Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study.
        ESMO open. 2020; 5e000698
        • Averitt AJ
        • Weng C
        • Ryan P
        • Perotte A.
        Translating evidence into practice: eligibility criteria fail to eliminate clinically significant differences between real-world and study populations.
        npj Digital Medicine. 2020; 3: 67
      2. NHS Health Research Authority. Service Evaluation Clinical/Non-Financial Audit Usual Practice [in Public Health Including Health Protection]. London: NHRA.

        • Sforza V
        • Martinelli E
        • Cardone C
        • et al.
        Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme.
        ESMO Open. 2017; 2e000229
        • Kwakman JJM
        • Vink G
        • Vestjens JH
        • et al.
        Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands.
        Int J Clin Oncol. 2018; 23: 482-489
        • Kasper S
        • Kisro J
        • Fuchs M
        • et al.
        Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer.
        BMC Cancer. 2018; 18: 1124
        • Cremolini C
        • Rossini D
        • Martinelli E
        • et al.
        Trifluridine/Tipiracil (TAS-102) in refractory metastatic colorectal cancer: a multicenter register in the frame of the italian compassionate use program.
        Oncologist. 2018; 23: 1178-1187
        • Kotani D
        • Shitara K
        • Kawazoe A
        • et al.
        Safety and efficacy of trifluridine/tipiracil monotherapy in clinical practice for patients with metastatic colorectal cancer: experience at a single institution.
        Clin Colorectal Cancer. 2016; 15: e109-e115
        • Iveson T
        • Carter AM
        • Shiu K-K
        • Spooner C
        • Stevens D
        • Mullamitha S.
        Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme.
        BMC Cancer. 2020; 20: 91
        • Skuja E
        • Gerina-Berzina A
        • Hegmane A
        • Zvirbule Z
        • Vecvagare E
        • Purkalne G.
        Duration of previous treatment as a prognostic factor in metastatic colorectal cancer treated with trifluridine/tipiracil.
        Mol Clin Oncol. 2018; 8: 699-702
        • Fernandez Montes A
        • Vazquez Rivera F
        • Martinez Lago N
        • et al.
        Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram.
        Clin Transl Oncol. 2020; 22: 351-359
        • Moriwaki T
        • Fukuoka S
        • Taniguchi H
        • et al.
        Propensity score analysis of regorafenib versus trifluridine/tipiracil in patients with metastatic colorectal cancer refractory to standard chemotherapy (REGOTAS): A Japanese Society for cancer of the colon and rectum multicenter observational study.
        Oncologist. 2018; 23: 7-15
        • Borelli B
        • Zucchelli G
        • Rossini D
        • et al.
        A retrospective study of trifluridine/tipiracil in pretreated metastatic colorectal cancer patients in clinical practice.
        Colorectal Cancer. 2018; 7: CRC01
        • Garcia-Alfonso P
        • Ruiz A
        • Carrato A
        • et al.
        Compassionate use program with FDT-TPI (trifluridine-tipiracil) in pre-treated metastatic colorectal cancer patients: Spanish real world data.
        J Clin Oncol. 2017; 35 (e15019-e15019)
        • Matsuda A
        • Yamada T
        • Matsumoto S
        • et al.
        Pretreatment Neutrophil-to-lymphocyte ratio predicts survival after TAS-102 treatment of patients with metastatic colorectal cancer.
        Anticancer Res. 2019; 39: 4343-4350
        • Nishina T
        • Yoshino T
        • Shinozaki E
        • et al.
        Onset of neutropenia as an indicator of treatment response in the randomized phase II of TAS-102 vs placebo in Japanese patients with metastatic colorectal cancer (Study J003-10040030).
        J Clin Oncol. 2016; 34 (3557-3557)
        • Kasi PM
        • Kotani D
        • Cecchini M
        • et al.
        Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study.
        BMC Cancer. 2016; 16: 467
        • Giuliani J
        • Bonetti A.
        The onset of grade ≥3 neutropenia is associated with longer overall survival in metastatic colorectal cancer patients treated with trifluridine/tipiracil.
        Anticancer Res. 2019; 39: 3967-3969
        • Makihara K
        • Fukui R
        • Uchiyama H
        • Shigeoka Y
        • Toyokawa A.
        Decreased percentage of neutrophil is a predict factor for the efficacy of trifluridine and tipiracil hydrochloride for pretreated metastatic colorectal cancer.
        J Gastrointest Oncol. 2019; 10: 878-885
        • Yoshino T
        • Cleary JM
        • Van Cutsem E
        • et al.
        Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials.
        Ann Oncol. 2020; 31: 88-95